1. Pink Sheet
  2. >>Advanced Technologies
  3. >>AI

US FDA’s Role In Artificial Intelligence/Machine Learning Development Is ‘Convener,’ Califf Says

 
• By Derrick Gingery

Speaking at the Consumer Electronics Show, FDA commissioner says agency and industry must work together to understand AI/ML and continuously assess the algorithms for efficacy.

Artificial intelligence
Califf said AI algorithm assessment needs to be continuous. • Source: Shutterstock

Robert Califf sees the US Food and Drug Administration learning about artificial intelligence along with industry and expects the agency will need outside help regulating the systems.

Hundreds of products using AI have been approved by the agency. But they have so-called closed algorithms, which cannot change over time. Learning algorithms, which improve as they receive more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

AI Could Be Used ‘In The Deliberation’ Of HTA Reviews In England, Says NICE

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.

EMA’s Newly Qualified AI Tool To Boost MASH Market Dynamics

 
• By Neena Brizmohun

The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.

More from Advanced Technologies